Skip to main content
. Author manuscript; available in PMC: 2024 May 13.
Published in final edited form as: Pain. 2022 Jan 25;163(10):1905–1918. doi: 10.1097/j.pain.0000000000002586

Table 3:

Proportion of participants with clinically meaningful improvement in average pain intensity and proportion endorsing any opioid analgesic medication use at each follow-up time by treatment group (no imputed data), and risk ratios comparing treatment groups

Proportion (95% Confidence Interval)a P-valueb Risk Ratio (95% Confidence Interval)e
ED HYP MM HYP vs. ED MM vs. ED MM vs. HYP
 Clinically Meaningful Responder (yes) Post-treatment 0.16 (0.09, 0.24) 0.12 (0.06, 0.19) 0.20 (0.13, 0.29) .29 0.75 (0.37, 1.51) 1.27 (0.69, 2.35) 1.70 (0.57, 2.83)
3-months 0.17 (0.10, 0.26) 0.20 (0.13, 0.29) 0.18 (0.11, 0.27) .80 1.20 (0.65, 2.19) 1.01 (0.52, 1.93) 0.84 (0.33, 1.36)
6-months 0.09 (0.04, 0.17) 0.26 (0.18, 0.36) 0.22 (0.15, 0.32) .02* 2.85 (1.35, 6.00)* 2.35 (1.09, 5.08)* 0.83 (0.39, 1.26)
 Using any opioid analgesic Medications (yes) Post-treatment 0.24 (0.16, 0.33) 0.20 (0.13, 0.29) 0.22 (0.15, 0.32) .003* 1.40 (1.11, 1.78)* 0.97 (0.69, 1.37) 0.69 (0.52, 0.86)*
3-months 0.23 (0.15, 0.33) 0.20 (0.13, 0.29) 0.26 (0.17, 0.36) .05* 1.28 (0.97, 1.68) 0.96 (0.67, 1.36) 0.75 (0.54, 0.96)*
6-months 0.25 (0.16, 0.35) 0.21 (0.14, 0.31) 0.24 (0.16, 0.34) .18 1.17 (0.87, 1.57) 0.85 (0.58, 1.24) 0.73 (0.47, 0.98)
*

Denotes significance at p < .05

a

Proportions based on complete dataset, and Jeffreys 95% confidence intervals

b

P-value from omnibus test for treatment group effect on being a responder to treatment (adjusting for pretreatment average pain intensity) or using opioid analgesic medications (adjusting for use at pretreatment) in a logistic regression.

c

Risk ratio estimates from a logistic regression with log-link for a responder to treatment (adjusting for pretreatment average pain intensity) or using opioid analgesic medication at posttreatment (adjusting for use at pretreatment)